Clinomics Europe – liquid biopsy – genetic testing

Clinomics Europe was established in Budapest in 2021 as the first EU subsidiary of Clinomics Inc., Korea. Our innovative, multiomics-based medical biotech company focuses on precision medicine and oncology. We develop novel molecular diagnostic tools based on cutting-edge technologies such as liquid biopsy, NGS (next-generation sequencing), real-time qPCR, dPCR, and more.

Minimally invasive and repeatable techniques such as liquid biopsy have significant advantages compared to gold-standard methods in oncology, enabling early diagnosis, real-time prognosis, and longitudinal therapy monitoring. Blood-based biomarkers such as circulating tumor cells (CTCs) and cell-free DNA and RNA are gaining attention as more sensitive and specific alternatives to traditional biomarkers. Our proprietary technology, the CD-Prime Lab-on-a-Disc platform enables the enrichment of intact, unlabelled CTCs and the plasma fraction containing ctDNA (circulating tumor DNA) and exosomes, maximizing the potential of liquid biopsy applications in oncology. By combining liquid biopsy with state-of-the-art molecular technologies, such as NGS, qPCR, and dPCR, we aim to take precision medicine to the next level.

Besides our core technology, we provide a wide range of R&D services in our well-equipped laboratories, offering customized liquid biopsy-based solutions for specific research projects. We also offer a broad selection of laboratory instruments and reagents. Read more about the full range of our activities at our website.
Hungarian based European genetic diagnostic laboratory specialized in CE IVD liquid biopsy solutions

Clinomics Europe
https://clinomicseurope.com/
https://www.instagram.com/clinomicseurope/
https://www.tiktok.com/@clinomicsdiag